What diseases does Sotorasib treat?

Sotorasib (Sotorasib) is a targeted therapy drug used to treat certain variants of the EGFR (epidermal growth factor receptor) gene in non-small cell lung cancer (NSCLC). The drug is primarily used to treat patients with NSCLC who have the KRAS G12C mutation, a cancer-causing variant that is common in this type of lung cancer. Sotorasiib acts on the KRAS G12C protein to inhibit its abnormal activity and block tumor growth signaling pathways. This novel drug provides a new treatment option for NSCLC patients whose disease cannot be controlled by traditional chemotherapy or other targeted therapies.

The new approval is based on preliminary results from a study that included124 patients with KRAS G12C-mutant non-small cell lung cancer who had previously received other treatments. In a clinical trial called CodeBreaK 100, sotorasiib shrank tumors in 36% of participants. These tumor responses lasted an average of 10 months. By contrast, standard therapies shrink tumors in less than 20% of NSCLC patients who relapse after previous treatment, and these effects are often short-lived.

SotoracibThe original drug has not yet been launched in China, so it is not covered by medical insurance. Domestic patients cannot yet purchase this drug. The price of Hong Kong original research versionsotorasibuSpecifications120mg*240 tablets is about RMB 80,000, and the European original research version 120mg*240 tablets is priced at about RMB 44,040 (the price may fluctuate due to the exchange rate), which is relatively expensive. There are also cheaper generic drugs for sale in other countries. The specifications of the Laos Element Pharmaceutical Factory are 120mg*56 tablets and the price is around 4800 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of foreign generic drugs are basically the same as the original drugs.